Encysive to start Thelin clinical trial in patients with diastolic heart failure

By Ted A. Knutson

Washington, March 6 - Encysive Pharmaceuticals Inc. said Monday it intends to begin a clinical trial to study the use of Thelin (sitaxsentan sodium), an endothelin A receptor antagonist, in patients with diastolic heart failure.

The study in diastolic heart failure is one of the company's previously undisclosed indications for oral Thelin.

Encysive is a Houston-based biotechnology company.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.